{"id":34445,"date":"2025-05-29T17:23:31","date_gmt":"2025-05-29T09:23:31","guid":{"rendered":"https:\/\/flcube.com\/?p=34445"},"modified":"2025-05-29T17:23:32","modified_gmt":"2025-05-29T09:23:32","slug":"genemind-biosciences-closes-rmb-280-million-series-c-round-to-fuel-dna-sequencer-innovation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34445","title":{"rendered":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation"},"content":{"rendered":"\n

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (SHA: 688289<\/a>), Kingmed Diagnostics (SHA: 603882<\/a>), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.<\/p>\n\n\n\n

Funding to Accelerate Innovation and Expansion<\/strong>
The proceeds from the financing will be allocated to further advance GeneMind’s technological leadership in the DNA sequencing space. Since its Series C financing in August 2023, the company has launched two flagship products: the SURFSeq 5000, the world’s highest-throughput desktop gene sequencer with a capacity of 2.2Tb per run, and the SURFSeq Q, the world\u2019s highest daily-output ultra-high-throughput sequencer, capable of delivering 9Tb per day. These innovations highlight GeneMind’s commitment to pushing the boundaries of genetic sequencing technology.<\/p>\n\n\n\n

Regulatory Approvals and Market Entry<\/strong>
GeneMind has achieved significant regulatory milestones with two of its products being approved as Class III medical devices by China’s National Medical Products Administration (NMPA). The GenoLab M Dx, approved in September 2024, stands as the first domestically produced high-throughput gene sequencer in China to employ the reversible termination sequencing method. Additionally, the FASTASeq 300 Dx, approved in April 2025, offers clinical advantages in speed, cost, and sample flexibility, further solidifying GeneMind’s position in the diagnostic landscape.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD…<\/p>\n","protected":false},"author":1,"featured_media":34446,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,2448,81,624,259,1593,906],"class_list":["post-34445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-genemind-biosciences","tag-genomics-ngs","tag-kingmed-diagnostics","tag-sansure-biotech","tag-sha-603882","tag-sha-688289"],"yoast_head":"\nGeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34445\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation\" \/>\n<meta property=\"og:description\" content=\"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34445\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T09:23:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T09:23:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation\",\"datePublished\":\"2025-05-29T09:23:31+00:00\",\"dateModified\":\"2025-05-29T09:23:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2913.webp\",\"keywords\":[\"Finance\",\"GeneMind Biosciences\",\"Genomics \\\/ NGS\",\"KingMed Diagnostics\",\"Sansure Biotech\",\"SHA: 603882\",\"SHA: 688289\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34445#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34445\",\"name\":\"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2913.webp\",\"datePublished\":\"2025-05-29T09:23:31+00:00\",\"dateModified\":\"2025-05-29T09:23:32+00:00\",\"description\":\"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34445\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2913.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2913.webp\",\"width\":1080,\"height\":608,\"caption\":\"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34445#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation - Insight, China's Pharmaceutical Industry","description":"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34445","og_locale":"en_US","og_type":"article","og_title":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation","og_description":"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.","og_url":"https:\/\/flcube.com\/?p=34445","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T09:23:31+00:00","article_modified_time":"2025-05-29T09:23:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34445#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34445"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation","datePublished":"2025-05-29T09:23:31+00:00","dateModified":"2025-05-29T09:23:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34445"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34445#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","keywords":["Finance","GeneMind Biosciences","Genomics \/ NGS","KingMed Diagnostics","Sansure Biotech","SHA: 603882","SHA: 688289"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34445#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34445","url":"https:\/\/flcube.com\/?p=34445","name":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34445#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34445#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","datePublished":"2025-05-29T09:23:31+00:00","dateModified":"2025-05-29T09:23:32+00:00","description":"Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (688289.SH), Kingmed Diagnostics (603882.SH), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34445#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34445"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34445#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","width":1080,"height":608,"caption":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34445#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2913.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34445"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34445\/revisions"}],"predecessor-version":[{"id":34447,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34445\/revisions\/34447"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34446"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}